ClinicalTrials.gg
RecruitingNCT06897930Updated Nov 18, 2026

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

A Phase 1/2 interventional study of AZD0120 and Cyclophosphamide in Lupus Erythematosus, Systemic, sponsored by AstraZeneca. Recruiting at 20 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 18, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.

Planned enrollment
12th of 26
150 · median 109
Started
2025
with 8 others
Phase 1/2
2 of 46
1 open now
Primary completion
2029-05
later than 15 of 24 live
Registered
33rd of 46
by date

Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 12th largest by planned enrollment of the 26 interventional ones that give a count, is one of 9 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 15 of the 24 other live ones, and was the 33rd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

Read the detailed description

The study will enrol adult participants with refractory Systemic Lupus Erythematosus (SLE) The study will be run in 2 parts;

First part is Phase 1b during which the study aims to assess safety and tolerability of AZD0120 in patients in refractory SLE cohorts

Second part is Phase 2, during which the study aims to assess safety, tolerability and efficacy of the selected dose, following Phase 1b completion, in patients with refractory SLE

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • AZD0120
  • SLE
  • Systemic Lupus Erythematosus
  • Lupus
  • Lupus Nephritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 through 70 years inclusive at the time of consent.
  2. Written in accordance with federal, local, and institutional guidelines.
  3. Must be able and willing to adhere to the study visit schedule and other protocol requirements
  4. Adequate hepatic, renal, pulmonary, and cardiac function
  5. Have a clinical diagnosis of SLE according to the EULAR/ American College of Rheumatology (ACR) 2019 criteria with a positive ANA ≥1:80 and a score ≥10.
  6. Have used at least two standard (including one biological agent).
  7. SLEDAI-2K score ≥6 at screening.
  8. Must include a significant SLE related organ involvement: arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, vasculitis, or renal.
  9. For lupus nephritis: Diagnosis of proliferative lupus nephritis based on a renal obtained within 6 months prior to signing the informed consent form or during the screening period Class III, IV or V LN according to the WHO 2003 ISN/RPS classification.

Exclusion criteria

EXCLUSION:

  1. Have received prior treatment with CAR T therapy directed at any target.
  2. Have received any therapy that is targeted to CD19 and/or BCMA
  3. Received allogenic stem cell transplant or stem cell transplant.
  4. An active that is progressing or requires active treatment.
  5. Primary immunodeficiency
  6. Active viral or bacterial infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    AZD0120

    Single dose of AZD0120

    Biological: AZD0120 · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • BiologicalAZD0120

    Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..

    Also known as: GC012F

  • Lymphodepletion - specified dose prior to receiving AZD0120

  • Lymphodepletion - specified dose prior to receiving AZD0120

06

What researchers measure

Primary outcomes

  1. PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)

    The incidence and severity of adverse events (AEs)

    Time frame: 2 years

  2. PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2

    To determine the recommended phase 2 dose (RP2D) of AZD0120

    Time frame: 2 years

  3. PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Proportion of participants achieving SRI-4 response

    Time frame: 2 years

Secondary outcomes

  1. PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Proportion of participants achieving SLE Responder Index 4 (SRI-4) response over time

    Time frame: 2 years

  2. PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Proportion of participants achieving remission in SLE (DORIS) remission over time

    Time frame: 2 years

  3. PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Proportion of participants achieving Lupus Low Disease Activity State (LLDAS) over time

    Time frame: 2 years

  4. PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Proportion of participants achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response over time

    Time frame: 2 years

  5. PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE

    Time from AZD0120 infusion and time from response to first disease flare

    Time frame: 2 years

  6. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    The area under the concentration-time curve (AUC) from time zero (T0) to the last measurable concentration time point (AUClast)

    Time frame: 2 years

  7. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))

    Time frame: 2 years

  8. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    The last measurable concentration of AZD0120 (Clast)

    Time frame: 2 years

  9. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    Maximum observed blood concentration (Cmax)

    Time frame: 2 years

  10. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    Terminal half-life of a drug during its elimination phase in pharmacokinetics (t1/2λz)

    Time frame: 2 years

  11. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    Time of the last measurable (quantifiable) concentration of a AZD0120 (Tlast)

    Time frame: 2 years

  12. PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE

    Time of maximum observed blood concentration (Tmax)

    Time frame: 2 years

  13. PHASE 1B & 2: To assess immunogenicity of AZD0120

    Presence of AZD0120 antibodies

    Time frame: 2 years

  14. PHASE 1B & 2: To determine whether replication-competent lentivirus is present in participants that receive AZD0120

    Presence of replication-competent lentivirus (RCL)

    Time frame: 2 years

  15. PHASE 2: To further characterize the safety of AZD0120 in participants with refractory SLE

    Further characterization of the safety of AZD0120 by measuring the incidence and severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: 2 years

  16. PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status

    To assess changes from baseline for Changes in Lupus Quality of life (LupusQoL)

    Time frame: 2 years

  17. PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status

    To assess changes from baseline for FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT)

    Time frame: 2 years

07

Study locations

13 of 20 sites recruiting
  • Research Site
    San Francisco, California 94143, United States
    Recruiting
  • Research Site
    Stanford, California 94304-2201, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Tampa, Florida 33612, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21287, United States
    Not yet recruiting
  • Research Site
    Bethesda, Maryland 20892, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Boston, Massachusetts 02115, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    Syracuse, New York 13202-2240, United States
    Recruiting
  • Research Site
    Chapel Hill, North Carolina 27599-7280, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Richmond, Virginia 23298, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Recruiting
  • Research Site
    Seattle, Washington 98195, United States
    Recruiting
  • Research Site
    Darlinghurst, 2010, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Toronto, Ontario M5T 2S8, Canada
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Bristol, BS1 3NU, United Kingdom
    Withdrawn

    Not enrolling at this site.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

Of 38 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 27, 2025
StartActual
Apr 21, 2025
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 5 sites changed recruiting status (3 now withdrawn, 2 now recruiting)
Show 5 sites
  • Research Site · Stanford, United StatesNot yet recruiting→Withdrawn
  • Research Site · Tampa, United StatesSuspended→Withdrawn
  • Research Site · Chicago, United StatesNot yet recruiting→Recruiting
  • Research Site · Melbourne, AustraliaNot yet recruiting→Recruiting
  • Research Site · Bristol, United KingdomNot yet recruiting→Withdrawn
Show site
  • Research Site · Toronto, Canada
Show 1 removed
  • Research Site · Toronto, Canada
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed. 5 sites changed recruiting status (3 now withdrawn, 2 now recruiting)
    Show 5 sites
    • Research Site · Stanford, United StatesNot yet recruiting→Withdrawn
    • Research Site · Tampa, United StatesSuspended→Withdrawn
    • Research Site · Chicago, United StatesNot yet recruiting→Recruiting
    • Research Site · Melbourne, AustraliaNot yet recruiting→Recruiting
    • Research Site · Bristol, United KingdomNot yet recruiting→Withdrawn
    Show site
    • Research Site · Toronto, Canada
    Show 1 removed
    • Research Site · Toronto, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06897930
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Apr 21, 2025
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion